Tealwood Asset Management Inc. Invests $1.32 Million in ADMA Biologics Inc $ADMA

Key Points

• Tealwood Asset Management opened a new position in ADMA Biologics, buying 72,087 shares valued at about $1.32 million, and institutional investors now own roughly 75.68% of the company.
• Insider activity included COO Kaitlin Kestenberg-Messina selling 10,096 shares for about $157,800 while Director Steve Elms purchased 7,000 shares, with corporate insiders collectively owning about 3.50% of the stock.
• ADMA reported Q4 EPS of $0.20 (in line with estimates) and revenue of $139.16M (up 18.4% YoY but slightly below expectations); the stock recently traded down ~4.7% and analysts have an average Buy rating with a $32 consensus target.

Tealwood Asset Management Inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 72,087 shares of the biotechnology company's stock, valued at approximately $1,315,000.

Other institutional investors have also bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in ADMA Biologics in the third quarter valued at $25,000. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,495 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 795 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at $34,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares of the company's stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the stock in a transaction on Thursday, March 5th. The stock was bought at an average price of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Trading Down 4.7%

Shares of ADMA opened at $14.32 on Friday. The stock has a fifty day moving average price of $16.33 and a two-hundred day moving average price of $16.64. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics Inc has a 52-week low of $13.76 and a 52-week high of $25.67. The company has a market cap of $3.41 billion, a price-to-earnings ratio of 23.87 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to analysts' expectations of $139.80 million. During the same quarter in the prior year, the business earned $0.46 earnings per share. The business's revenue for the quarter was up 18.4% on a year-over-year basis. Analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ADMA. Wall Street Zen upgraded shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Zacks Research raised shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.00.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.